Meta-Analysis:
Clinical significance of sarcopenia in the treatment of patients with primary hepatic malignancies a systematic review and metaanalysis
PDF | Full Text | How to cite
Metrics: PDF 2119 views | Full Text 3170 views
Guoqing Zhang1, Songfeng Meng1, Renfeng Li1, Jianwen Ye1 and Longshuan Zhao1
1Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
Correspondence to:
Longshuan Zhao, email: [email protected]
Keywords: sarcopenia; hepatocellular carcinoma; intrahepatic cholangio-carcinoma; third lumbar skeletal muscle index; third lumbar total psoas area
Received: February 25, 2017 Accepted: June 05, 2017 Published: July 28, 2017
ABSTRACT
Background: The impact of sarcopenia on outcomes following treatment for primary liver tumors remains contentious. Therefore, we performed a systematic literature review and meta-analysis to evaluate the clinical significance of sarcopenia in the treatment of patients with primary liver tumors.
Data sources: A systematic literature search was performed in English through February 1, 2017 in databases.
Results: There were significant differences between patients with and without sarcopenia in overall 1- and 3-year survival (1 year: OR: 0.43; 95% CI: 0.27-0.68; P=0.0004; 3 year: OR: 0.67; 95% CI: 0.47-0.96; P=0.03). However, overall 5-year survival showed no significant difference between the groups (OR: 0.61; 95% CI: 0.35-1.07; P=0.08). Patients with sarcopenia showed a significant 53% reduction in disease-free survival within 5 years (OR: 0.47; 95% CI: 0.28-0.79; P=0.005). Also, sarcopenia had a significantly negative impact on recurrence in patients with primary liver tumors (RR: 2.71; 95% CI: 1.46-5.05; P=0.002). Regarding complications rate, we concluded that there was a statistically significant difference between two groups in overall complications rate (RR: 2.52; 95% CI: 1.50-4.22; P=0.0005). However, the major complications rate showed no significant difference between the groups (RR: 1.19; 95% CI: 0.65-2.20; P=0.57).
Conclusions: Sarcopenia seemed to have a negative effect on overall survival in patients with primary liver tumors in the early phase post-treatment, but further research is needed to investigate the prognostic impact on overall survival over the longer term. Moreover, sarcopenia could significantly increase the incidence rates of post-treatment recurrence and overall complications in patients with primary liver tumors.